Supplementary methods for the analysis of the Delis-Kaplan Executive Function System (Delis, Kaplan, & Kramer, 2001) are made available, including (a) quantifying the number of abnormally low achievement scores exhibited by an individual and accompanying this with an estimate of the percentage of the normative population expected to exhibit at least this number of low scores; (b) estimating the overall abnormality of an individual's achievement score profile with the Mahalanobis distance index; (c) calculating a composite executive function index score for an individual and providing accompanying confidence limits; and (d) providing the percentile ranks for an individual's achievement scores and executive index score (in the latter case, confidence limits on scores are also expressed as percentile ranks). With the exception of the Mahalanobis distance index, all the methods can be obtained with the equations and tables provided in this article. However, for the convenience of clinicians and to reduce the possibility of clerical error, the methods have also been implemented in a computer program. More important, the program allows the methods to be applied when only a subset of scores is available. The program can be downloaded (as a zip file) from this article's supplemental materials or from www.abdn.ac.uk/~psy086/dept/DKEFS_Supplementary_Analysis.htm.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1037/a0023712 | DOI Listing |
Objective: To explore the lived experiences and extent of cognitive symptoms in Long COVID (LC) in a UK-based sample.
Design: This study implemented a mixed-methods design. Eight focus groups were conducted to collect qualitative data, and the Framework Analysis was used to reveal the experiences and impact of cognitive symptoms.
J Prev Alzheimers Dis
February 2025
Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Background: Cognitive training (CT) has been one of the important non-pharmaceutical interventions that could delay cognitive decline. Currently, no definite CT methods are available. Furthermore, little attention has been paid to the effect of CT on mood and instrumental activities of daily living (IADL).
View Article and Find Full Text PDFJ Prev Alzheimers Dis
February 2025
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA; School of Behavioral and Brain Sciences, University of Texas at Dallas, Dallas, TX, USA.
Background: Recent disease-modifying treatments for Alzheimer's disease show promise to slow cognitive decline, but show no efficacy towards reducing symptoms already manifested.
Objectives: To investigate the efficacy of a novel noninvasive brain stimulation technique in modulating cognitive functioning in Alzheimer's dementia (AD).
Design: Pilot, randomized, double-blind, parallel, sham-controlled study SETTING: Clinical research site at UT Southwestern Medical Center PARTICIPANTS: Twenty-five participants with clinical diagnoses of AD were enrolled from cognition specialty clinics.
Age Ageing
January 2025
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Background: A mobile cognition scale for community screening in cognitive impairment with rigorous validation is in paucity. We aimed to develop a digital scale that overcame low education for community screening for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and AD.
Methods: A mobile cognitive self-assessment scale (CogSAS) was designed through the Delphi process, which is feasible for the older population with low education.
Ann Clin Transl Neurol
January 2025
NEUROFARBA Department, Neurosciences Section, University of Florence, Florence, Italy.
Objectives: We aim to investigate cognitive phenotype distribution and MRI correlates across pediatric-, elderly-, and adult-onset MS patients as a function of disease duration.
Methods: In this cross-sectional study, we enrolled 1262 MS patients and 238 healthy controls, with neurological and cognitive assessments. A subset of 222 MS patients and 92 controls underwent 3T-MRI scan for brain atrophy and lesion analysis.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!